InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Full Year Statutory Accounts - YE 31 March 2016 22 Jun 2016 2:21PM $0.310 $0.360 risen by 16.13%
- Rights Issue Cleansing Notice 10 Jun 2016 9:33AM $0.290 $0.360 risen by 24.14%
- Rights Issue Booklet 10 Jun 2016 9:32AM $0.290 $0.360 risen by 24.14%
- Appendix 3B - Rights Issue 10 Jun 2016 9:25AM $0.290 $0.360 risen by 24.14%
- Placement & Rights Issue to Raise Additional Working Capital 10 Jun 2016 9:24AM $0.290 $0.360 risen by 24.14%
- Preliminary Final Report - YE 31 March 2016 31 May 2016 4:27PM $0.270 $0.360 risen by 33.33%
- Video of Corporate Presentation 3 May 2016 11:45AM $0.295 $0.360 risen by 22.03%
- Appendix 4C - Statement of Cashflows March 2016 Qtr 29 Apr 2016 9:24AM $0.280 $0.360 risen by 28.57%
- Appendix 3B - Employee Options 28 Apr 2016 10:09AM $0.340 $0.360 risen by 5.88%
- Change of Director's Interest Notice - Michael Quinn 19 Apr 2016 1:07PM $0.200 $0.360 risen by 80%
- Investment Presentation 18 Apr 2016 10:14AM $0.190 $0.360 risen by 89.47%
- Trial Recruitment Complete - Interview with CEO 15 Apr 2016 10:33AM $0.175 $0.360 risen by 105.71%
- Clinical Trial Fully Enrolled and Strong Interest 13 Apr 2016 8:20AM $0.165 $0.360 risen by 118.18%
- Change of Director's Interest Notice - Andrew Sneddon 9 Mar 2016 7:25PM $0.175 $0.360 risen by 105.71%
- Change of Director's Interest Notice - Andrew Sneddon 2 Mar 2016 9:32AM $0.190 $0.360 risen by 89.47%
- Appendix 4C - Dec 2015 Quarterly Cash Flow Report 29 Jan 2016 9:28AM $0.175 $0.360 risen by 105.71%
- Appendix 3B - Quotation - End of Restriction Period 24 Dec 2015 11:10AM $0.200 $0.360 risen by 80%
- Change of Director's Interest - A Sneddon Options Expired 18 Dec 2015 10:29AM $0.200 $0.360 risen by 80%
- Change of Director's Interest - C Collins Options Expire 18 Dec 2015 10:27AM $0.200 $0.360 risen by 80%
- Change of Director's Interest - M Quinn Options Expire 18 Dec 2015 10:22AM $0.200 $0.360 risen by 80%
- Securities to be Released from Escrow 8 Dec 2015 9:20AM $0.190 $0.360 risen by 89.47%
- Half Yearly Report and Accounts 30 Nov 2015 6:22PM $0.220 $0.360 risen by 63.64%
- Change in substantial holding - Christopher Collins 23 Nov 2015 8:27AM $0.200 $0.360 risen by 80%
- Change of Director's Interest - Andrew Sneddon - Placement 20 Nov 2015 11:39AM $0.200 $0.360 risen by 80%
- Change of Director's Interest - Michael Quinn - Placement 20 Nov 2015 11:38AM $0.200 $0.360 risen by 80%

126 - 150 of 191 results

Page 6 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.